Skip to main content
. 2022 Apr 29;14(9):2222. doi: 10.3390/cancers14092222

Figure 4.

Figure 4

Gefitinib resistance is highly dependent on the total amount of DAG in H1650 cells. (A) H1650 cells were transfected with siRNAs for LPIN1 and treated with a PLCγ inhibitor (5 μM) or a vehicle in combination with varying gefitinib concentrations. The gefitinib sensitivity of each cell line was determined using varying gefitinib concentrations. (B) H1650 cells were transfected with siRNAs for LPIN1 and treated with the PLCγ inhibitor (5 μM) or vehicle in combination with gefitinib (5 μM) or DMSO for 96 h; cell growth was measured using 0.5% crystal violet staining. (C) H1650 cells were transfected with siRNAs for LPIN1, treated with PLCγ inhibitor (5 μM) or vehicle in combination with gefitinib (5 μM) or DMSO for 72 h, and harvested to detect their PKC activity. (D) H1650 cells were treated with propranolol (50 μM), PLCγ inhibitor (5 μM) or vehicle in combination with gefitinib (5 μM) or DMSO for 24 h and harvested to determine p-IκBα expression levels. Values are the mean ± SD of three independent experiments. Statistical significance was determined by (B) two-way ANOVA or (C) Student’s t-test (**, p < 0.01; ***, p < 0.001; ****, p < 0.0001; and NS, not significant).